Search research articles
Contact Us
Filters
Showing results (71-80 of 187) with videos related to
Page
of 19
Sort By:
British Journal of Haematology
|
September 4, 2008
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
Barbara Pro, Brian Leber, Mitchell Smith, et al.
Clinical Trials (London, England)
|
May 8, 2016
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting
Ajay K Gopal, Barbara Pro, Joseph M Connors, et al.
Leukemia & Lymphoma
|
March 22, 2024
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma
Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2003
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
Issa F Khouri, Ming-S Lee, Rima M Saliba, et al.
Blood Advances
|
June 16, 2023
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
Jia Ruan, Jasmine Zain, Brett Palmer, et al.
Leukemia & Lymphoma
|
March 8, 2017
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials
Andrei Shustov, Bertrand Coiffier, Steven Horwitz, et al.
Cancer
|
June 16, 2010
Marginal zone lymphomas: factors that affect the final outcome
Ali Mazloom, L Jeffrey Medeiros, Peter W McLaughlin, et al.
Cancer
|
July 13, 2002
International prognostic index-based outcomes for diffuse large B-cell lymphomas
Richard B Wilder, Maria A Rodriguez, L Jeffrey Medeiros, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study
Francine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Blood Neoplasia
|
September 15, 2025
Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant
Brian Cuzzo, Maegan Ford, Saagar Jain, et al.
Page
of 19
Search research articles
Search
Showing results (71-80 of 187) with videos related to
Sort By:
Page
of 19
British Journal of Haematology
|
September 4, 2008
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
Barbara Pro, Brian Leber, Mitchell Smith, et al.
Clinical Trials (London, England)
|
May 8, 2016
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting
Ajay K Gopal, Barbara Pro, Joseph M Connors, et al.
Leukemia & Lymphoma
|
March 22, 2024
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma
Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2003
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
Issa F Khouri, Ming-S Lee, Rima M Saliba, et al.
Blood Advances
|
June 16, 2023
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
Jia Ruan, Jasmine Zain, Brett Palmer, et al.
Leukemia & Lymphoma
|
March 8, 2017
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials
Andrei Shustov, Bertrand Coiffier, Steven Horwitz, et al.
Cancer
|
June 16, 2010
Marginal zone lymphomas: factors that affect the final outcome
Ali Mazloom, L Jeffrey Medeiros, Peter W McLaughlin, et al.
Cancer
|
July 13, 2002
International prognostic index-based outcomes for diffuse large B-cell lymphomas
Richard B Wilder, Maria A Rodriguez, L Jeffrey Medeiros, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study
Francine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Blood Neoplasia
|
September 15, 2025
Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant
Brian Cuzzo, Maegan Ford, Saagar Jain, et al.
Page
of 19